Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
PF-06835919
AOB11409
CAS 2102501-84-6
Chemical Name: 2-((1R,5S,6R)-3-(2-((S)-2-Methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetic acid
1000 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $32.04 | Total: $160.19 |
| 1 | 10 | $27.14 | Total: $271.38 |
| 1 | 25 | $22.99 | Total: $574.81 |
| 1 | 50 | $19.60 | Total: $980.00 |
| 1 | 100 | $16.96 | Total: $1,696.15 |
Overview
Novel potent inhibitor of ketohexokinase (KHK)
Chemical Properties
| Molecular Formula | C16H19F3N4O2 |
| Molecular Weight | 356.35 |
| CAS Numbers | 2102501-84-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | (1α,5α,6α)-3-[2-[(2S )-2-methyl-1-azetidinyl]-6-(trifluoromethyl)-4-pyrimidinyl]-3-azabicyclo[3.1.0]hexane-6-acetic acid |
| InChl Key | MDUYWDNWFXSMJJ-XWLWVQCSSA-N |
| InChl Code | InChI=1S/C16H19F3N4O2/c1-8-2-3-23(8)15-20-12(16(17,18)19)5-13(21-15)22-6-10-9(4-14(24)25)11(10)7-22/h5,8-11H,2-4,6-7H2,1H3,(H,24,25)/t8-,9-,10-,11+/m0/s1 |
| SMILES Code | OC(C[C@H]1[C@@]2([H])[C@]1([H])CN(C3=NC(N4CC[C@@H]4C)=NC(C(F)(F)F)=C3)C2)=O |
Storage and Handling
0C Short Term -20C Long Term
Synonyms
Ketohexokinase Inhibitor 1
References
1) Futatsugi, K., Smith, A., Tu, M., et al. Discovery of PF-06835919: A potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose. J. Med. Chem. 63(22), 13546-13560 (2020).
2) Gutierrez, J.A., Liu, W., Perez, S., et al. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Mol. Metab. 48, 101196 (2021).